Status:
UNKNOWN
Tranexamic Acid Reduce Blood Loss in Meningioma Resection
Lead Sponsor:
Chiang Mai University
Conditions:
Meningioma
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
In neurosurgical setting, a large sample size trials of tranexamic acid (TXA) has been limited to TBI and SAH. The evidence of TXA in brain tumor was scarce. A few case reports support the role of TX...
Detailed Description
Background and Literature review: 1. Meningioma 2. Coagulation in craniotomy to remove meningioma 3. Bleeding in craniotomy to remove meningioma 4. Tranexamic acid (TXA) 5. Knowledge gap The topics s...
Eligibility Criteria
Inclusion
- The patients whose aged 18 to 60 years
- The patients who was diagnosed intracranial meningioma
- The radio-graphic finding of tumor diameter \> 5 cm in at least 2 dimensions
- The patients have written informed consent
- The patients is scheduled for elective craniotomy to remove tumor
Exclusion
- Patients who refuse to participate in this study
- Patients with recurrent tumor
- The patient is set operation for intracranial tissue biopsy
- The patients with history of TXA allergy
- The pregnant patients
- The patients with history of significant thromboembolic episode
- The patients with significant renal dysfunction (GFR ≤ 50 ml/min)
Key Trial Info
Start Date :
September 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT04386642
Start Date
September 1 2021
End Date
September 30 2022
Last Update
January 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chiang Mai University
Chiang Mai, Thailand, 50200